Bryan Gillis
Nessuna posizione attualmente
Provenienza dei contatti di primo grado di Bryan Gillis
| Entità | Tipo di entità | Settore Industriale | |
|---|---|---|---|
| Private Company | Biotechnology | 22 | |
| Public Company | Medical/Nursing Services | 8 |
Grafico delle società connesse in secondo grado
Relazione in diverse aziende
Società connesse a Bryan Gillis tramite i suoi contatti personali
| Società | Settore | Persone collegate | Posizione principale |
|---|---|---|---|
| ROCHE HOLDING AG | Pharmaceuticals: Major | Public Communications Contact | |
| BIOGEN INC. | Pharmaceuticals: Major | Corporate Officer/Principal Chief Tech/Sci/R&D Officer | |
| NOVO NORDISK A/S | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal | |
| ALCON INC. | Medical Specialties | Director of Finance/CFO | |
| RADIUS HEALTH, INC. | Biotechnology | Director of Finance/CFO Investor Relations Contact | |
| NOVARTIS AG | Pharmaceuticals: Major | Corporate Officer/Principal | |
| Stanford University | College/University | Undergraduate Degree Undergraduate Degree | |
| University of Pennsylvania | College/University | Doctorate Degree | |
University of Southern California
 University of Southern California Other Consumer ServicesConsumer Services University of Southern California is a private research university that mainly offers undergraduate, graduate & other higher education. The university was founded in 1880 and is headquartered in Los Angeles, CA. | College/University | Masters Business Admin Doctorate Degree | |
| BLUEBIRD BIO, INC. | Biotechnology | General Counsel Corporate Officer/Principal | |
Flagship Pioneering
 Flagship Pioneering Investment ManagersFinance Flagship Pioneering (Flagship Pioneering) is a venture capital firm founded in 1982 by Ed M Kania and Noubar B Afeyan. The firm is headquartered in Cambridge, Massachusetts. | Investment Managers | Private Equity Investor Private Equity Investor Private Equity Investor Private Equity Investor | |
| McGill University | College/University | Doctorate Degree Doctorate Degree | |
| University of London | College/University | Doctorate Degree | |
| Tufts University | College/University | Undergraduate Degree Undergraduate Degree | |
| Pepperdine University | College/University | Masters Business Admin | |
| Rensselaer Polytechnic Institute | College/University | Graduate Degree | |
| University of North Texas | College/University | Undergraduate Degree | |
| AVACTA GROUP PLC | Miscellaneous Commercial Services | Chief Executive Officer | |
International Institute of New England, Inc.
 International Institute of New England, Inc. Services to the Health IndustryHealth Services International Institute of New England, Inc. operates as a non-profit organization serving immigrants, refugees, asylees, and other vulnerable populations. Its services include refugee resettlement, case management, health services navigation, employment, education and literacy and citizenship programming. The company was founded in 1910 and is headquartered in Boston, MA. | Services to the Health Industry | Director/Board Member | |
| AMAG PHARMACEUTICALS, INC. | Pharmaceuticals: Major | General Counsel Corporate Officer/Principal | |
| Universidad Técnica Federico Santa María | College/University | Undergraduate Degree | |
| KARYOPHARM THERAPEUTICS INC. | Pharmaceuticals: Major | Investor Relations Contact | |
Warp Drive Bio, Inc.
 Warp Drive Bio, Inc. Miscellaneous Commercial ServicesCommercial Services Warp Drive Bio, Inc. focused on proprietary genomic technology to discover drugs of natural origin. The firm deployed proprietary platforms Genome Mining and Small Molecule Assisted Receptor Targeting (SMART) to discover and develop novel molecules addressing new pharmacologic mechanisms. The company was founded by Gregory L. Verdine, George McDonald Church, and James A. Wells in 2012 and was headquartered in Cambridge, MA. | Miscellaneous Commercial Services | Corporate Officer/Principal | |
| ADC THERAPEUTICS SA | Pharmaceuticals: Major | Director of Finance/CFO | |
| Columbia Business School | College/University | Masters Business Admin | |
Adare Pharma Solutions, Inc.
 Adare Pharma Solutions, Inc. Pharmaceuticals: MajorHealth Technology Adare Pharma Solutions, Inc. provides pharmaceutical outsourcing services. Its technologies are used to develop novel prescription and OTC products. Its brands include Viactiv, and Lactéol. The company was founded in 1999 and is headquartered in Lawrenceville, NJ. | Pharmaceuticals: Major | Corporate Officer/Principal | |
| Northeastern University School of Law | College/University | Graduate Degree Graduate Degree | |
| The Lally School of Management & Technology | College/University | Masters Business Admin | |
| CODIAK BIOSCIENCES | Pharmaceuticals: Major | Director/Board Member | |
| INNOCOLL HOLDINGS PLC | Pharmaceuticals: Major | Director of Finance/CFO | |
Tmunity Therapeutics, Inc.
 Tmunity Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Tmunity Therapeutics, Inc. develops novel products that free the immunological potential of T cells to treat disease indications. It develops novel T Cell Receptor (TCR) engineered T cells, regulatory T cells (Treg), and universal engineered T cell platforms. The company was founded by Carl H. June, Anne Chew, Bruce Levine, Yangbing Zhao, James L. Riley and Bruce Blazar and is headquartered in Philadelphia, PA. | Miscellaneous Commercial Services | Chief Tech/Sci/R&D Officer | |
| LANDOS BIOPHARMA, INC. | Biotechnology | Director/Board Member | |
Ohana Biosciences, Inc.
 Ohana Biosciences, Inc. Miscellaneous Commercial ServicesCommercial Services Ohana Biosciences, Inc. operates early stage biotechnology firm. The company is headquartered in Cambridge, MA. | Miscellaneous Commercial Services | Corporate Officer/Principal | |
Cygnal Therapeutics, Inc.
 Cygnal Therapeutics, Inc. BiotechnologyHealth Technology Cygnal Therapeutics, Inc. develops drugs for cancer, immunological diseases and regenerative processes. The company was founded by Noubar Afeyan, Avak Kahvejian and Jordi Mata-Fink in 2017 and is headquartered in Cambridge, MA. | Biotechnology | Founder | |
HotSpot Therapeutics, Inc.
 HotSpot Therapeutics, Inc. BiotechnologyHealth Technology HotSpot Therapeutics, Inc. develops new allosteric therapies with the ability to treat disease. The company was founded by Jonathan Montagu and Geraldine Harriman and is headquartered in Boston, MA. | Biotechnology | Director/Board Member | |
Ring Therapeutics, Inc.
 Ring Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Ring Therapeutics, Inc. engages in the development of a gene therapy platform. Its Anellovector platform provides tissue specifities benefitting from the inherent diversity of tropism afforded by the commensal virome. The company was founded in 2000 and is headquartered in Cambridge, MA. | Pharmaceuticals: Major | Director/Board Member Chief Executive Officer | |
Cellarity Inc.
 Cellarity Inc. BiotechnologyHealth Technology Cellarity Inc. engages in the operation of platform to design medicines targeting the full cellular and molecular complexity of disease. The company was founded by Avak Kahvejian, James J. Collins, Noubar Afeyan, and Nicholas Plugis in 2017 and is headquartered in Cambridge, MA. | Biotechnology | Founder | |
Catamaran Bio, Inc.
 Catamaran Bio, Inc. Financial ConglomeratesFinance Catamaran Bio, Inc. provides investment services. The company is headquartered in Delaware. | Financial Conglomerates | Chief Operating Officer Corporate Officer/Principal | |
Generate Biomedicines, Inc.
 Generate Biomedicines, Inc. BiotechnologyHealth Technology Generate Biomedicines, Inc. is a drug generation company that has developed a machine learning-powered multimodality generative biology platform capable of generating new drugs on demand across a wide range of biologic modalities. Generate Biomedicines is based in Somerville, MA. The platform seamlessly integrates computational and wet lab capabilities, improving the speed at which targets and therapeutics are identified and validated, the specificity of target engagement by generated proteins, and the cost of identifying and developing clinical candidates. The company's platform represents a potentially fundamental shift in what's possible in the field of therapeutic development, addressing key challenges of drug discovery and drastically expanding the available search space for novel biomedicines. The company was founded in 2018 by Poorya Hosseini, Molly Gibson, Geoffrey von Maltzahn, Avak Kahvejian, Gevorg Grigoryan. Michael T. Nally has been the CEO of the company since 2018. | Biotechnology | Founder | |
Cytoimmune Therapeutics, Inc.
 Cytoimmune Therapeutics, Inc. BiotechnologyHealth Technology Cytoimmune Therapeutics, Inc. is a clinical-stage biotechnology company founded in 2017 and based in Toa, Japan. The American company is focused on developing a pipeline of NK cell therapies for various types of cancer, including lung cancer, acute myeloid leukemia, solid tumors, and multiple myeloma. The private company's lead product, Cyto-102, is a track-NK cell therapy that aims to enter clinical trials in combination with atezolizumab for non-small cell lung cancer in 2022. Cytoimmune Therapeutics also offers cell therapy development and clinical manufacturing services to biotechnology companies and academia. The company's state-of-the-art clinical cell manufacturing facility is custom-built to support the development and commercialization of cutting-edge T cell or NK cell therapies. The company was founded in 2017 by Michael A. Caligiuri, William Michael Rosellini, and Jianhua Yu, Ph.D. José Eduardo Vidal has been the CEO of the company since 2021. | Biotechnology | Chief Executive Officer | |
Profound Therapeutics
 Profound Therapeutics Pharmaceuticals: OtherHealth Technology Profound Therapeutics is a company that is focused on discovering new medicines by expanding the human proteome. The company is based in Cambridge, MA. The company uses their platform, Profoundry, to identify and validate proteins and understand their therapeutic potential. This results in a growing database of novel proteins and their roles in health and disease. The company was founded in 2020 by Avak Kahvejian, who has been the CEO since then. | Pharmaceuticals: Other | Chief Executive Officer | |
Aprinoia Therapeutics, Inc. /US/
 Aprinoia Therapeutics, Inc. /US/ BiotechnologyHealth Technology Aprinoia Therapeutics, Inc. operates as a global clinical-stage biopharmaceutical company. It develops imaging diagnostic tools, targeted therapy drugs, and other products. The company was founded in 2015 and is headquartered in Cambridge, MA. | Biotechnology | Director/Board Member | |
| Silicon Therapeutics, Inc. | Chairman | ||
Ampersand Biomedicines
 Ampersand Biomedicines BiotechnologyHealth Technology Ampersand Biomedicines is an American company that designs programmable medicines that work precisely where needed in the body and nowhere else. The company's computationally powered platform identifies ideal addresses for drug localization and informs the design of and-body™ therapeutics that have the optimal therapeutic effect. The result is smarter biologic medicines that target the site of disease without affecting healthy tissue or cells. Ampersand is enabling potent mechanisms to treat disease by creating and programming therapeutics that are more efficacious, without compromising on safety or tolerability. The company was founded in 2020 at Flagship Labs, a unit of Flagship Pioneering. Jason Gardner has been the CEO of the company since 2023. | Biotechnology | Founder |
Statistiche
Distribuzione geografica
| Stati Uniti | 41 |
| Svizzera | 5 |
| Regno Unito | 3 |
| Danimarca | 2 |
| Canada | 2 |
Settori
| Health Technology | 27 |
| Consumer Services | 14 |
| Commercial Services | 8 |
| Finance | 3 |
| Health Services | 2 |
Posizioni
| Corporate Officer/Principal | 67 |
| Director/Board Member | 54 |
| Undergraduate Degree | 22 |
| Chief Tech/Sci/R&D Officer | 20 |
| Chief Executive Officer | 19 |
Contatti più connessi
| Insiders | |
|---|---|
| Roger Pomerantz | 30 |
| Gregory Perry | 16 |
| Joseph Vittiglio | 14 |
| Anne Prener | 14 |
| Natalie Holles | 13 |
| Avak Kahvejian | 13 |
| Mark F. Boshar | 13 |
| Torben Nissen | 12 |
| Andrew Oh | 12 |
| Jose Carmona | 11 |
| Laurence Turka | 10 |
| Nathan Dowden | 9 |
| Anne Marie Conway | 9 |
| Maiken Keson-Brookes | 8 |
| Dannielle Appelhans | 7 |
- Borsa valori
- Insiders
- Bryan Gillis
- Connessioni Società
